Presently, except that presurgical prognosis relies largely on age and Karnofsky Performance Status (KPS), no convincing prognostic and predictive factors have been prevalent in clinical management of GBM patients, although several prognostic and predictive markers or models have been proposed or developed, such as MGMT promoter methylation[25], BRAF fusions and IDH1 mutations[26], subclassification based on gene expression[2], Immunohistochemical analysis[27] and Volume-Age-KPS (VAK) prognostic model related with MR-imaging[28]. This evidence concerns the gene MGMT and glioblastoma.